Clay Siegall is the co-founder of Seattle Genetics which was established in 1998. He is the company’s chief executive officer, president and the chairman to the board. He is a scientist by training and concentrates on cancer therapies. His passion for helping patients led him to establish Seattle Genetics through drug development practices, scientific innovation and vast research. Under his leadership the company has made a name for itself in the development of cancer drugs. First, the company has come up with antibody-drug conjugates and acquired approval in 2011 for the sale of the first product. Seattle Genetics is advancing a wide pipeline of proprietary business that can supply the antibody-drug conjugates that will be channeled towards treatment of cancer.
Due to the aggressive nature of Siegall Genetics has acquired multiple licenses aimed at facilitating the antibody drug conjugated technology. Such licenses include those with prominent organizations such as GlaxoSmithKline and Genentech. In addition to the above, there are more than twenty Anti-body conjugates clinical developments using Seattle technology. Moreover, Dr. Siegall has also participated in finance raising activities of the organization both from the private and public sector. He took part in the initial public offer that was conducted in the year 2001. Due to his good work and his expertise in science he has won a few awards which are; 2013 University of Maryland alumnus of the year award and 2012 Pacific Northwest Ernst and Young entrepreneur of the year.
“Genes that preserve health; genes that block cancer development” is one of the most recent articles by Clay Siegall. It talks about the discovery of the modifier genes that can fight cancer. It prevents cancer by blocking inflammations therefore preventing colon cancer despite exposure to foods that cause cancer. The article clearly demonstrated how the modifier genes could be used appropriately to prevent the disease. The other article is about FenoLogica Biosciences signing licensing and collaboration agreements with Pacific North West Research Institute giving scientist access to the research institute. The avenue created will help scientist research on the causes of diseases and treatment available for the same. It will make the work easier through the high technology and insights that come with the agreements.